Management of Adverse Events during Treatment of Tuberculosis in the Patient with Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Management of Adverse Events during Treatment of Tuberculosis in the Patient with Systemic Lupus Erythematosus

Published:2023-08-29 Issue:4 Volume:101 Page:80-86
ISSN:2542-1506
Container-title:Tuberculosis and Lung Diseases
language:
Short-container-title:Tuberk. bolezni lëgk.

Author:

Romanova M. I.¹^ORCID,Vaniev E. V.¹^ORCID,Churkin D. O.¹^ORCID,Abramchenko A. V.²^ORCID,Gayda A. I.¹^ORCID,Lovacheva O. V.¹^ORCID,Samoylova A. G.¹^ORCID

Affiliation:

1. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health

2. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health

Abstract

The article describes a clinical case of chemotherapy for drug susceptible rapidly progressive pulmonary tuberculosis in a patient with systemic lupus erythematosus taking glucocorticosteroids on regular basis. Due to adverse events that occurred when using the regimen of first line drugs, the patient discontinued taking first line drugs and was immediately switched to second line drugs. A timely decision to completely cancel the chemotherapy regimen with first line drugs that caused AE, the immediate start of the individual regimen (Bq, Lzd, Lfx, and Tzd) made it possible to cure pulmonary and bronchial tuberculosis in this patient. At the same time, data were obtained on the effective and safe use of tuberculosis treatment regimen (Bq, Lzd, Lfx, and Tzd) while taking GCS for SLE.

Publisher

LLC "Medical Knowledge and Technologies"

Subject

General Medicine

Reference11 articles.

1. Klyukvina N. G. The problem of comorbidity in systemic lupus erythematosus. RMJ, 2015, no. 7, pp. 370. (In Russ.)

2. de Luis A., Pigrau C., Pahissa A., Fernández F., Martínez-Vázquez J. M. Infecciones en 96 casos de lupus eritematoso sistémico. Med. Clin (Barc), 1990, vol. 95, no. 1, pp. 24. PMID: 2381245.

3. Falagas M. E., Voidonikola P. T., Angelousi A. G. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int. J. Antimicrob. Agents, 2007, vol. 30, no. 6, pp. 477-486. https://doi.org/10.1016/j.ijantimicag.2007.07.010

4. Janwityanuchit S., Totemchokchyakarn K., Krachangwongchai K., Vatanasuk M. Infection in systemic lupus erythematosus. J. Med. Assoc. Thai., 1993, vol. 76, no. 10, pp. 542-548. PMID: 7964223.

5. Jick S. S., Lieberman E. S., Rahman M. U., Choi H. K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis. Rheum., 2006, vol. 55, no. 1, pp. 19-26.